Open AccessPathologic complete response rate according to HER2 detection methods in HER2-positive breast cancer treated with neoadjuvant systemic therapy
Author(s) -
Melissa Krystel-Whittemore,
Jin Xu,
Edi Brogi,
Katia Ventura,
Sujata Patil,
Dara S. Ross,
Chau T. Dang,
Mark E. Robson,
Larry Norton,
Monica Morrow,
Hannah Y. Wen
Publication year - 2019
Publication title -
breast cancer research and treatment
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.908
H-Index - 154
eISSN - 1573-7217
pISSN - 0167-6806
DOI - 10.1007/s10549-019-05295-9
Subject(s) - breast cancer , immunohistochemistry , medicine , oncology , progesterone receptor , fluorescence in situ hybridization , estrogen receptor , cancer , breast carcinoma , pathology , neoadjuvant therapy , biology , biochemistry , chromosome , gene
Human epidermal growth factor receptor 2 (HER2)-positive breast cancers are known to have significant clinical and pathological response to neoadjuvant systemic therapy (NST). The aim of this study was to identify factors associated with pathological complete response (pCR), defined as no residual invasive carcinoma in the breast and axillary lymph nodes (ypT0/is ypN0), among patients with HER2-positive breast cancer and to compare pCR rates between breast cancers with HER2 protein overexpression by immunohistochemistry (IHC) versus HER2 gene amplification by fluorescence in situ hybridization (FISH) in the absence of protein overexpression by IHC.